Analyst Conference Summaries

Biotechnology Investor Aids

Avidity Biosciences
RNA

conference date: November 8, 2022 (press relase only)

Avidity Biosciences Has A Promising RNA Therapy Platform [January 12, 2020 at Seeking Alpha]

2022
Avidity
Biosciences
Q4 2021
Avidity
Biosciences
Q1 2022
Avidity
Biosciences
Q2 2022
Avidity
Biosciences
Q3 2022
March 1, 2022 May 10, 2022 Aug. 9, 2022 Nov. 8, 2022
2021
Avidity
Biosciences
Q4 2020
Avidity
Biosciences
Q1 2021
Avidity
Biosciences
Q2 2021
Press Release
Avidity
Biosciences
Q3 2021
summary
March 16, 2021 May 12, 2021 August 9, 2021 November 9, 2021

Avidity Biosciences (RNA) is a preclinical-stage biotechnology company specializing in a novel RNA therapy platform, antibody oligonucleotide conjugates or AOCs, for diseases caused by genetic mutations.

Avidity Biosciences web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 DRNA
 EPZM
 GILD
 GLYC
 ILMN
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 SAGE
 SGEN
 VBLT
 VSTM
 WBA
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2021 William P. Meyers